BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 23910665)

  • 1. Ipragliflozin does not prolong QTc interval in healthy male and female subjects: a phase I study.
    Zhang W; Smulders R; Abeyratne A; Dietz A; Krauwinkel W; Kadokura T; Keirns J
    Clin Ther; 2013 Aug; 35(8):1150-1161.e3. PubMed ID: 23910665
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of single doses of maraviroc on the QT/QTc interval in healthy subjects.
    Davis JD; Hackman F; Layton G; Higgins T; Sudworth D; Weissgerber G
    Br J Clin Pharmacol; 2008 Apr; 65 Suppl 1(Suppl 1):68-75. PubMed ID: 18333868
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized, double-blind, crossover study to investigate the effect of rivaroxaban on QT-interval prolongation.
    Kubitza D; Mueck W; Becka M
    Drug Saf; 2008; 31(1):67-77. PubMed ID: 18095747
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized, crossover, placebo- and moxifloxacin-controlled study to evaluate the effects of bosutinib (SKI-606), a dual Src/Abl tyrosine kinase inhibitor, on cardiac repolarization in healthy adult subjects.
    Abbas R; Hug BA; Leister C; Sonnichsen D
    Int J Cancer; 2012 Aug; 131(3):E304-11. PubMed ID: 22065400
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of sugammadex doses up to 32 mg/kg alone or in combination with rocuronium or vecuronium on QTc prolongation: a thorough QTc study.
    de Kam PJ; van Kuijk J; Prohn M; Thomsen T; Peeters P
    Clin Drug Investig; 2010; 30(9):599-611. PubMed ID: 20568829
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of the effect of Naloxegol on cardiac repolarization: a randomized, placebo- and positive-controlled crossover thorough QT/QTc study in healthy volunteers.
    Gottfridsson C; Carlson G; Lappalainen J; Sostek M
    Clin Ther; 2013 Dec; 35(12):1876-83. PubMed ID: 24238792
    [TBL] [Abstract][Full Text] [Related]  

  • 7. No effect of a single supratherapeutic dose of lersivirine, a next-generation nonnucleoside reverse transcriptase inhibitor, on corrected QT interval in healthy subjects.
    Vourvahis M; Wang R; Ndongo MN; O'Gorman M; Tawadrous M
    Antimicrob Agents Chemother; 2012 May; 56(5):2408-13. PubMed ID: 22371898
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preladenant, a selective adenosine A₂A receptor antagonist, is not associated with QT/QTc prolongation.
    Wang Z; Xuan F; Lin WH; Troyer MD; Tendolkar A; Cutler DL
    Eur J Clin Pharmacol; 2013 Oct; 69(10):1761-7. PubMed ID: 23857248
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of levetiracetam on cardiac repolarization in healthy subjects: a single-dose, randomized, placebo- and active-controlled, four-way crossover study.
    Hulhoven R; Rosillon D; Bridson WE; Meeus MA; Salas E; Stockis A
    Clin Ther; 2008 Feb; 30(2):260-70. PubMed ID: 18343264
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of nalmefene 20 and 80 mg on the corrected QT interval and T-wave morphology: a randomized, double-blind, parallel-group, placebo- and moxifloxacin-controlled, single-centre study.
    Matz J; Graff C; Vainio PJ; Kallio A; Højer AM; Struijk JJ; Kanters JK; Andersen MP; Toft E
    Clin Drug Investig; 2011 Nov; 31(11):799-811. PubMed ID: 21967071
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of the effects of bitopertin (RG1678) on cardiac repolarization: a thorough corrected QT study in healthy male volunteers.
    Hofmann C; Banken L; Hahn M; Swearingen D; Nagel S; Martin-Facklam M
    Clin Ther; 2012 Oct; 34(10):2061-71. PubMed ID: 22980315
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Eltrombopag does not affect cardiac repolarization: results from a definitive QTc study in healthy subjects.
    Matthys G; Park JW; McGuire S; Wire MB; Zhang J; Bowen C; Williams D; Jenkins JM; Peng B
    Br J Clin Pharmacol; 2010 Jul; 70(1):24-33. PubMed ID: 20642544
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Thorough QT study of the effects of vildagliptin, a dipeptidyl peptidase IV inhibitor, on cardiac repolarization and conduction in healthy volunteers.
    He YL; Zhang Y; Serra D; Wang Y; Ligueros-Saylan M; Dole WP
    Curr Med Res Opin; 2011 Jul; 27(7):1453-63. PubMed ID: 21609207
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiac repolarization with Gabapentin enacarbil in a randomized, double-blind, placebo- and active-controlled, crossover thorough QT/QTc study in healthy adults.
    Davy M; Upward J; Arumugham T; Twomey C; Chen C; Stier B
    Clin Ther; 2013 Dec; 35(12):1964-74. PubMed ID: 24290737
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of Therapeutic and Supratherapeutic Doses of Siponimod (BAF312) on Cardiac Repolarization in Healthy Subjects.
    Shakeri-Nejad K; Aslanis V; Veldandi UK; Mooney L; Pezous N; Brendani B; Juan A; Allison M; Perry R; Legangneux E
    Clin Ther; 2015 Nov; 37(11):2489-2505.e2. PubMed ID: 26519230
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lamotrigine does not prolong QTc in a thorough QT/QTc study in healthy subjects.
    Dixon R; Job S; Oliver R; Tompson D; Wright JG; Maltby K; Lorch U; Taubel J
    Br J Clin Pharmacol; 2008 Sep; 66(3):396-404. PubMed ID: 18662287
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiac safety of indacaterol in healthy subjects: a randomized, multidose, placebo- and positive-controlled, parallel-group thorough QT study.
    Khindri S; Sabo R; Harris S; Woessner R; Jennings S; Drollmann AF
    BMC Pulm Med; 2011 May; 11():31. PubMed ID: 21615886
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of the Effect of Selumetinib on Cardiac Repolarization: A Randomized, Placebo- and Positive-controlled Crossover QT/QTc Study in Healthy Subjects.
    Zhou D; So K; Dymond AW; Vik T; Al-Huniti N; Mariani G; Zorenyi G; Huang Y; Holmes V; Severin P; Rasmussen S; Martin P
    Clin Ther; 2016 Dec; 38(12):2555-2566. PubMed ID: 27837934
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Repeated supratherapeutic dosing of strontium ranelate over 15 days does not prolong QT(c) interval in healthy volunteers.
    Taubel J; Naseem A; Wang D; Arezina R; Lorch U; Camm AJ
    Br J Clin Pharmacol; 2012 Aug; 74(2):296-303. PubMed ID: 22283848
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lack of effect of perampanel on QT interval duration: Results from a thorough QT analysis and pooled partial seizure Phase III clinical trials.
    Yang H; Laurenza A; Williams B; Patten A; Hussein Z; Ferry J
    Epilepsy Res; 2015 Aug; 114():122-30. PubMed ID: 26088895
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.